Acute cardiac care & resuscitationCohort study
Impact of Advanced Cardiac Life Support Medications on Discharge Neurological Function for Survivors of Cardiac Arrest When Using ECPR
- retrospective Extracorporeal Life Support Organization registry-based analysis
- inverse probability treatment weights
- cumulative odds models
Authors' conclusion
Our data support that increasing doses of epinephrine and nonantiarrhythmic advanced cardiovascular life support medications both worsen the probability of neurologically intact survival for patients who undergo extracorporeal cardiopulmonary resuscitation.
Study context
- Population
- Patients cannulated for veno-arterial extracorporeal membrane oxygenation during cardiac arrest (extracorporeal cardiopulmonary resuscitation)
- Exposure
- Association between either (1) binary receipt of a medication or (2) the number of epinephrine milligrams given, and cerebral performance category (CPC) score
- Outcome
- cerebral performance category (CPC) score
- Follow-up
- Hospital discharge
Main finding
As reported in the abstract
Odds ratio (95% CI)P value
amiodaroneCPC ≤ 1
1.28(1.00–1.65)
P = 0.048amiodaroneCPC ≤ 2
1.38(1.06–1.78)
P = 0.015lidocaineCPC ≤ 1
1.69(1.32–2.17)
P < 0.001lidocaineCPC ≤ 2
1.82(1.39–2.38)
P < 0.001lidocaineCPC ≤ 3
1.76(1.30–2.40)
P < 0.001sodium bicarbonateCPC ≤ 2; lower likelihood
0.63(0.49–0.81)
P < 0.001sodium bicarbonateCPC ≤ 3; lower likelihood
0.65(0.49–0.86)
P = 0.003- epinephrine · unweighted cumulative effects model; dose-dependent increasing relationship between epinephrine doses and harm for all CPC levels
- OR 0.89-0.94; P < 0.001 for all
Observational data: associations, not effects.
Original publication
Impact of Advanced Cardiac Life Support Medications on Discharge Neurological Function for Survivors of Cardiac Arrest When Using ECPR. Circ Heart Fail. Published 7 January 2026. doi:10.1161/circheartfailure.125.013420
Summarised from the published abstract; every number is checked against it